Sanjeev Gill

1.8k total citations
25 papers, 503 citations indexed

About

Sanjeev Gill is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sanjeev Gill has authored 25 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Sanjeev Gill's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Sanjeev Gill is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Sanjeev Gill collaborates with scholars based in Australia, United States and South Korea. Sanjeev Gill's co-authors include Peter Bergin, Catriona McLean, Rebecca Tay, Elizabeth F. Blackley, Andrew Haydon, Timothy Price, Harri A. Järveläinen, Andrew Dean, Razi Ghori and Corinne Maurice‐Dror and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Sanjeev Gill

24 papers receiving 495 citations

Peers

Countries citing papers authored by Sanjeev Gill

Since Specialization

Citations

This map shows the geographic impact of Sanjeev Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanjeev Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanjeev Gill more than expected).

Fields of papers citing papers by Sanjeev Gill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanjeev Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanjeev Gill. The network helps show where Sanjeev Gill may publish in the future.

Co-authorship network of co-authors of Sanjeev Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Sanjeev Gill. A scholar is included among the top collaborators of Sanjeev Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanjeev Gill. Sanjeev Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort 2025 ·Cancer ·Sun Young Rha, Eduardo Castañón, Sanjeev Gill, Hélène Senellart, Juanita Lopez, Iván Márquez‐Rodas, Iván Victoria, Tae Min Kim, Zarnie Lwin, Michael C. Burger, Matteo Simonelli, Philippe A. Cassier, Andrew Hendifar, (unknown), Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, Luis J. Villanueva-Rivera	1
2	The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data. 2023 ·Journal of Clinical Oncology ·Michael Michael, Rachel Wong, Sanjeev Gill, Andrew Strickland, Nick Pavlakis, Jeremy Shapiro, Emma Link, (unknown), Samuel Y. Ngan, Alexander G. Heriot, David Goldstein, Catherine Mitchell, (unknown), (unknown), Robert G. Ramsay, Eva Segelov	1
3	Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study 2022 ·The Lancet. Gastroenterology & hepatology ·Andrew Dean, Sanjeev Gill, Mark D. McGregor, (unknown), Harri A. Järveläinen, Timothy Price	48
4	LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort. 2021 ·Journal of Clinical Oncology ·Hyun Cheol Chung, Zarnie Lwin, Carlos Gomez‐Roca, Federico Longo, Eduardo Yáñez, (unknown), Donna M. Graham, Mark Doherty, Philippe A. Cassier, Juanita Lopez, Bristi Basu, Andrew Hendifar, Corinne Maurice‐Dror, Sanjeev Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Esma Saâda-Bouzid	4
5	Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. 2021 ·Journal of Clinical Oncology ·Luis J. Villanueva-Rivera, Zarnie Lwin, Hyun Cheol Chung, Carlos Gomez‐Roca, Federico Longo, Eduardo Yáñez, Hélène Senellart, Mark Doherty, Javier García-Corbacho, Andrew Hendifar, Corinne Maurice‐Dror, Sanjeev Gill, Tae Won Kim, Daniel Heudobler, Nicolas Penel, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Donna M. Graham	49
6	LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. 2021 ·Journal of Clinical Oncology ·Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im, (unknown), Hélène Senellart, (unknown), Javier García-Corbacho, Juanita Lopez, Bristi Basu, Corinne Maurice‐Dror, Sanjeev Gill, Razi Ghori, Peter Kubiak, (unknown), Kevin Norwood, Hyun Cheol Chung	53
7	1528P Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer 2020 ·Annals of Oncology ·Andrew Dean, Sanjeev Gill, (unknown), (unknown), Harri A. Järveläinen, Timothy Price	11
8	Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial. 2019 ·Journal of Clinical Oncology ·Michael Michael, Rachel Wong, Sanjeev Gill, David Goldstein, Sam Ngan, Alexander G. Heriot, Emma Link, (unknown), Paul J. Neeson, Robert G. Ramsay, (unknown), Catherine Mitchell, Jeanne Tie, Nick Pavlakis, John Zalcberg, Eva Segelov	4
9	Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma 2017 ·Gastric Cancer ·(unknown), Andrew Martin, Emma Gibbs, Katrin Marie Sjoquist, Nick Pavlakis, John Simes, Timothy Price, Jenny Shannon, Sanjeev Gill, Vikram Jain, Geoffrey Liu, George Kannourakis, Yeul Hong Kim, Jin Won Kim, David Goldstein	18
10	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy 2017 ·British Journal of Cancer ·Rebecca Tay, Elizabeth F. Blackley, Catriona McLean, (unknown), Peter Bergin, Sanjeev Gill, Andrew Haydon	84
11	Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of ¹³¹I-huA33 with Concurrent Capecitabine 2014 ·Journal of Nuclear Medicine ·Rebecca Herbertson, Niall C. Tebbutt, Fook-Thean Lee, Sanjeev Gill, Bridget Chappell, (unknown), Timothy Saunder, Graeme O’Keefe, Aurora Poon, Sze Ting Lee, Roger Murphy, Wendie Hopkins, Fiona E. Scott, Andrew M. Scott	24
12	Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. 2011 ·Journal of Clinical Oncology ·Jeffrey A. Sloan, M. R. Mahoney, Daniel J. Sargent, (unknown), (unknown), Ethan Basch, A. F. Shields, (unknown), R. M. Goldberg, Sanjeev Gill, Morton S. Kahlenberg, Steven R. Alberts	16
13	Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. 2011 ·Journal of Clinical Oncology ·Jin Huang, Daniel J. Sargent, M. R. Mahoney, A. F. Shields, Edward M. Chan, Richard M. Goldberg, Sanjeev Gill, Morton S. Kahlenberg, (unknown), T. C. Smyrk, Axel Grothey, Frank A. Sinicrope, (unknown), Steven R. Alberts	1
14	An Impact of Cross Over Operator on the Performance of Genetic Algorithm Under Operating System Process Scheduling Problem 2011 ·Rajiv Kumar, Sanjeev Gill, (unknown)	16
15	Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. 2010 ·Journal of Clinical Oncology ·Richard M. Goldberg, Daniel J. Sargent, S. N. Thibodeau, M. R. Mahoney, A. F. Shields, Elcie Chan, Sanjeev Gill, Morton S. Kahlenberg, S. Asha Nair, Steven R. Alberts	36
16	Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC). 2010 ·Journal of Clinical Oncology ·Han Chong Toh, (unknown), Brian I. Carr, (unknown), Sanjeev Gill, (unknown), (unknown), Justin L. Ricker, Dawn M. Carlson, Wei Peng Yong	16
17	Medullary carcinoma of the thyroid in a patient with colon cancer and a rising carcinoembryonic antigen level 2009 ·Internal Medicine Journal ·Sanjeev Gill, Walter Cosolo, Rebecca Herbertson, Salvatore U. Berlangieri, Andrew M. Scott	0
18	Targeted chemoradiation for metastatic colorectal cancer: A phase I trial of oral capecitabine combined with ¹³¹I- huA33 2007 ·Journal of Clinical Oncology ·Rebecca Herbertson, Niall C. Tebbutt, Sanjeev Gill, (unknown), Bridget Chappell, (unknown), Effie Skrinos, Aurora Poon, Timothy Saunder, Andrew M. Scott	1
19	A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen 2007 ·Clinical Cancer Research ·Andrew M. Scott, Niall C. Tebbutt, Fook-Thean Lee, (unknown), Zhanqi Liu, Sanjeev Gill, Aurora Poon, Wendie Hopkins, Fiona E. Smyth, Carmel Murone, Duncan MacGregor, Anthony T. Papenfuss, Bridget Chappell, Timothy Saunder, Martin W. Brechbiel, Ian D. Davis, Roger Murphy, Geoffrey Chong, Eric W. Hoffman, Lloyd J. Old	55
20	A phase I single dose escalation trial of ch806 in patients with advanced tumors expressing the 806 antigen 2006 ·Journal of Clinical Oncology ·Andrew M. Scott, Sanjeev Gill, (unknown), Z. Liu, Effie Skrinos, Carmel Murone, Timothy Saunder, Bridget Chappell, Anthony T. Papenfuss, Lloyd J. Old	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact